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Abstract
Background: To analyze the demographics, indications, and surgical outcomes of anophthalmic surgery
(enucleation and evisceration) at Jordan University Hospital during a 5-year period.
Methods: We conducted a retrospective chart review of patients who had undergone evisceration or enucleation
between August 2006 and June 2011. The data collected included age at time of surgery, sex, affected eye, surgical
indication, implant size, and postoperative complications.
Results: Anophthalmic surgery was performed for 68 eyes of 67 patients during the study period (42 (62 %)
eviscerations and 26 (38 %) enucleations). Forty-three patients (64 %) were men, and 40 (59 %) eyes were right
eyes. Trauma was the leading cause for anophthalmic surgery in 40 % of cases followed by a blind painful eye
secondary to glaucoma (19 %) in the enucleation group and endophthalmitis (28.6 %) in the evisceration group.
The most common anophthalmic surgery complication was wound dehiscence in 11.5 % of patients in the
enucleation and 9.5 % in the evisceration groups. The mean and median sizes of the implants for evisceration were
16.6 and 18.0 mm, respectively; for enucleation, both were 20 mm.
Conclusions: Evisceration was the preferred anophthalmic surgery in our series unless contraindicated. Trauma was
the most common predisposing factor for evisceration and enucleation in our tertiary care center followed by blind
painful eyes and endophthalmitis. The most common complication was wound dehiscence in both groups.
Background
Enucleation, the surgical removal of the entire globe,
and evisceration, the complete removal of the intraocu-
lar contents through a corneal or a scleral incision, with
preservation of the conjunctiva, sclera, extraocular mus-
cles, orbital fat and the optic nerve, have been acceptable
therapeutic modalities to treat various ocular conditions,
such as; intraocular tumors (enucleation only), severe
eye trauma, and blind, painful, cosmetically disfiguring
eyes over the last two centuries [1, 2].
Evisceration is a technically easier surgery to perform
compared with enucleation, causes less disruption of the
orbital anatomy, and may have fewer complications such
as ptosis, implant migration and extrusion, socket con-
tracture, and the deep superior sulcus syndrome [3, 4].
The current practice patterns that reflect the recent lit-
erature and historic trends were revealed by a recent
national survey of evisceration and enucleation practice
patterns in the United States, where two-thirds of oph-
thalmic plastic and reconstructive surgeons preferred
evisceration over enucleation when the underlying cause
of painful eye was benign; and implant exposure was the
most commonly encountered complication after both
surgeries [5, 6].
The usual indications for evisceration are unresponsive
endophthalmitis and for improvement of cosmesis in a
blind eye, while enucleation is indicated for the previous
two conditions as well as for painful blind eye, intraocular
malignancy, severe ocular trauma, phthisis with degener-
ation, and in congenital anophthalmia or severe micro-
phthalmia [1, 2, 4–7]. In a review of 24,444 enucleation
cases over a 55-year period, Spraul and Grossniklaus [7]
found trauma to account for 40.9 % of cases, whereas tu-
mors were the cause of enucleation in 24.2 % of cases. In
the other hand Chaudhry et al. [8] found endophthalmitis
to account for 45.5 % of cases, whereas phthisis bulbi and
trauma together were the cause of 39.5 % of cases.
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We conducted this retrospective study to determine
the underlying ocular conditions leading to anophthal-
mic surgery (enucleation and evisceration) in a tertiary
care center in Jordan and to evaluate the surgical out-
comes of both surgeries.
Methods
A retrospective review of the medical records of 67 pa-
tients who had undergone anophthalmic surgery (evis-
ceration or enucleation) between August 2006 and June
2011 in the Department of Ophthalmology, Jordan Uni-
versity Hospital was carried on. All patients who had
their anophthalmic surgery at Jordan University Hospital
during the study period were included. The study proto-
col adhered to the tenets of the Declaration of Helsinki
and was approved by the local institutional review board
and ethics committee (IRB at Jordan University Hospital
and The Faculty of Medicine). Patients were only ex-
cluded if they failed to complete 12 months of follow up.
Patients who had a second anophthalmic procedure (in
cases of implant exchange); the first procedure was used
for statistical analysis. The data collected included the
patients’ demographics, indications for anophthalmic
surgery, type of anophthalmic surgery, affected eye, size
and type of orbital implant, duration of follow-up, and
complications encountered during the follow-up period.
Enucleation was performed mainly for patients for
whom evisceration was contraindicated; when an intra-
ocular tumor could not be ruled out by clinical examin-
ation or imaging, or when it was difficult to perform
evisceration due to severe phthisis bulbi or irreparable
ocular rupture. When performing a fundus examination
to rule out an intraocular tumor was impossible due to
media opacity, a B-scan ultrasonography and orbital
magnetic resonance imaging (MRI) were performed pre-
operatively. Statistical analysis was performed using the
IBM SPSS Statistics version 20.0 (IBM Corporation,
Somers, New York, USA) and the independent samples
t-test was used to compare the enucleation and eviscer-
ation statistical means and fisher’s exact test to compare
postoperative anophthalmic surgical complications.
Surgical technique
All patients provided fully informed written consent for
surgery including an explanation of the possible postop-
erative complications. All surgeries were performed
under general anesthesia.
For enucleation, a retrobulbar injection of 5 ml of
50:50 Bupivacaine HCL with lidocaine and 1:100,000
adrenaline were administered, a 360° peritomy was per-
formed at the limbus and the four quadrants were
bluntly dissected to release the conjunctiva and Tenon’s
capsule from the globe. The medial and lateral recti
muscles were identified and sutured near the insertion
with 4–0 silk suture. Bipolar cautery was applied to the
four recti muscles near their insertions where they were
cut and disinserted from the globe. The dissection con-
tinued posteriorly, and the superior and inferior oblique
muscles were cut. The globe was retracted anteriorly
using the two silk sutures and a long curved hemostat
was secured around the optic nerve as posterior as pos-
sible. The optic nerve was transected with a blunt
curved enucleation scissor while the medial and lateral
recti insertions were held under traction using the silk
sutures and the loose globe was removed. After
hemostasis was achieved with bipolar diathermy and
pressure applications with icepacks, a sterile, silicone im-
plant was inserted primarily in the orbital socket poster-
ior to the posterior Tenon’s capsule to replace the lost
orbital volume. The implant size was estimated depend-
ing on the age of the patient and the size of the orbit
using the trial set that allows tension-free closure of the
anterior surface tissues. Tenon’s capsule (posterior and
anterior) and conjunctiva were closed in layers using 5–
0 and 6–0 polyglactin sutures (Vicryl, Ethicon Inc.),
respectively.
For evisceration, a 360° peritomy was created, and a
stab incision was made in the sclera about 1 to 2 mm
from the surgical limbus with a no. 11 blade scalpel. The
incision was continued circumferentially around the lim-
bus with Wescott scissors. An evisceration spoon was
used to separate the uveal tissue from the scleral shell,
and the globe contents were removed. The optic disc
was cauterized and the inside of the scleral shell was
cleaned and debrided. Anterior relaxing incisions were
made in the sclera nasally and temporally, avoiding the
medial and lateral rectus muscles. An appropriately sized
silicone sphere implant that allowed scleral closure with-
out undue tension was inserted primarily (as with enu-
cleation) in All cases. The scleral shell was closed with
5–0 polyglactin (Vicryl, Ethicon Inc.) in a horizontal
mattress sutures. The anterior Tenon’s capsule and con-
junctiva were closed in layers with 5–0 and 6–0 poly-
glactin (Vicryl, Ethicon Inc.) sutures, respectively. The
entire globe (enucleation) or intraocular contents (evis-
ceration) were sent for histopathological examination in
all cases.
A medium or large conformer was inserted, and anti-
biotic ointment was placed on the ocular surface. Two
frost sutures (4–0 silk) were applied over a bolster for
2 weeks and an eye patch was applied for 1 week. In-
traoperatively, the patients received an intravenous
broad-spectrum antibiotic and were discharged on oral
antibiotics for 10 days. The conformer was maintained
for 6 to 8 weeks. Further follow-up visits were sched-
uled for 1, 2, 4, 6, and 8 weeks, 3 months, and every
3 months thereafter to examine the socket for possible
complications.
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Results
Sixty-eight eyes of 67 patients underwent enucleation or
evisceration at Jordan University Hospital between Au-
gust 2006 and June 2011. The mean follow-up duration
was 24 months (range, 12–42 months). Twenty-five pa-
tients (26 eyes, 38 %) underwent enucleation and 42 pa-
tients (42 eyes, 62 %) underwent evisceration. The
patients’ demographics are summarized in Table 1. In
the enucleation group, one woman had bilateral enucle-
ation secondary to severe facial trauma while in motor
vehicle accident. The mean age at the time of surgery
was 38.8 ± 24.8 years. (Range, 1–85 years). The differ-
ence in mean age between the evisceration (47.12 ±
24.11 years) and enucleation (25.24 ± 16.50 years) sub-
groups was statistically significant (p = 0.001). Two-
thirds of our patients (69 % of eviscerated eyes and 64 %
of enucleated eyes) had a history of a previous ocular
surgery mainly; ruptured globe repair, cataract surgery,
or penetrating keratoplasty.
Severe trauma was the leading reason for anophthal-
mic surgery at our hospital in 40 % (n = 27/68) of cases;
(50 % (n = 13/26) in the enucleation group and 33.3 %
(n = 14/42) in the evisceration group). The second most
common indication for enucleation was a blind, painful, ir-
ritable eye with phthisis bulbi and degeneration secondary
to absolute glaucoma and accounted for 19 % (5/26) of
cases. In the evisceration group, endophthalmitis was the
second most common indication in 28.6 % (12/42)
followed by keratitis (23.8 %) (Table 2). Two of the cases of
enucleation had intraocular retinoblastoma and one had a
choroidal melanoma. The indications of anophthalmic sur-
gery (enucleation or evisceration) according to age and
gender are shown in Tables 3 and 4, respectively.
All the removed eyes were replaced initially with sili-
cone orbital implants at the time of primary surgery.
The mean and median implant sizes were 16.6 and
18.0 mm respectively (range, 8–22), in the evisceration
group (Fig. 1). In the enucleation group, the mean and
median implant sizes were 20 mm (range, 12–24) (Fig. 2).
The difference between the two groups was statistically
significant (p = 0.001).
After anophthalmic surgery, implant exposure or
extrusion developed in 8.8 % (n = 6/68) of cases (11.5 %
[n = 3/26] in the enucleation group and 7.1 % [n = 3/42]
of cases in the evisceration group). Implant migration lat-
erally occurred in 3.8 % (n = 1/26) of the enucleated eyes
but none in the eviscerated eyes. Ten percent (n = 7/68) of
the entire group was complicated by partial wound dehis-
cence (11.5 % [n = 3/26] in the enucleation group and
9.5 % [n = 4/42] in the evisceration group) with no statis-
tical difference found between both groups (Table 5).
Overall, 67.6 % of patients (46/68) (71.4 % of the eviscer-
ation group and 61.5 % of the enucleation group) did not
report any complication postoperatively during the fol-
low-up period. Two-thirds of the complications were
managed conservatively (observation for small wound
dehiscence or minimal implant exposure, or with sys-
temic antibiotics); patients with implant extrusion re-
quired replacement with a smaller implant size or a
dermis-fat graft (in one patient), and 8 % required re-
suturing of the wound. Sympathetic ophthalmia did not
develop in any case.
Discussion
Controversy remains regarding the advantages and dis-
advantages of each procedure [9, 10]. In the past, most
surgeons preferred enucleation for various indications
mainly because of the fear of sympathetic ophthalmia
that can occur after evisceration. [11] sympathetic oph-
thalmia, a potentially devastating and blinding auto-
immune condition characterized by panuveitis, in which
the injured eye incites inflammation in the fellow sympa-
thizing eye, was first reported in association with eviscer-
ation in 1887 [12, 13]. Even though evisceration and
enucleation surgeries successfully control pain, [14] many
surgeons believe that enucleation controls pain better
than evisceration and evisceration is more painful post-
operatively than enucleation, [14, 15] and because of the
fear of sympathetic ophthalmia, [11] enucleation previ-
ously was preferred by most surgeons for various indica-
tions. However, Shah-Desai et al. [16] found that ultimate
pain relief was achieved in all patients after enucleation
or evisceration at an average of 3 months with no differ-
ence in postoperative pain between the eviscerated or
enucleated groups [16] and recent studies have reported
that evisceration is safe and associated with a low risk of
sympathetic ophthalmia [17, 18].
Table 1 Patients’ demographic data
Characteristic Enucleation (26 eyes) Evisceration (42 eyes)
Mean age (years) 25.24 ± 16.50 47.12 ± 24.11
Range (years) 1–63 3–85
Men/women 15/10 28/14
Affected eye 14 right/12 left 26 right/16 left




Severe trauma 14/13 33.3 % / 50 %
Glaucoma 5/5 12 % / 19.2 %
Endophthalmitis 12/1 28.6 % / 3.8 %
Keratitis 10/2 23.8 % / 7.7 %
Behcet’s disease 1/2 2.4 % / 7.7 %
Tumors 0/3 0 % / 11.5 %
Total 42/26 100 % / 99.9 %
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Evisceration recently has become increasingly popular
for many reasons [19]; there is no solid evidence that
evisceration is associated with an increased risk of sym-
pathetic ophthalmia [20] and the surgery requires less
manipulation and consequently less inflammation and
scarring of orbital tissues and extraocular muscles result-
ing in better implant motility and cosmetic outcome
than enucleation [9, 21]. Furthermore, evisceration is
simpler, faster, and associated with lower risk of bleeding
intraoperatively and fewer postoperative complications,
such as ptosis, implant migration, implant extrusion,
socket contracture, and the deep superior sulcus syn-
drome [8, 21–23]. Similarly, we preferred performing
evisceration rather than enucleation unless contraindi-
cated or not feasible; therefore, 62 % of our patients in
the current study underwent evisceration rather than
enucleation. The most common cause of anophthalmic
surgery in our series was trauma in 40 % of cases
followed by a blind painful eye secondary to absolute
glaucoma with phthisis bulbi and degeneration in the
enucleation group and endophthalmitis in the eviscer-
ation group.
Moshfeghi et al. conducted a review of enucleation
and reported trauma as the leading indication for enu-
cleation worldwide and for 40.9 % of cases in the United
States, [24] and trauma has been the leading cause for
both types of anophthalmic surgeries in some reports
[10, 25–29]. Similarly, trauma was the reason for most
cases of anophthalmic surgery in the current series,
mainly for ocular trauma patients who presented with
no light perception (NLP) vision, expulsion of the intra-
ocular contents, and lacerations involving zone III.
Trauma accounted for 40 % of the indications in our
series (50 % in the enucleation group, and 33.3 % in the
evisceration group). In cases with extensive globe disrup-
tion, removal of all uveal tissue may be difficult via evis-
ceration; therefore, enucleation may better safeguard
against retained uveal tissue. However, in cases in which
the sclera is largely intact, and the intraocular contents
are contained and identifiable, evisceration may be a rea-
sonable alternative based on surgeon preference and ex-
perience [30, 31]. However, post-traumatic early
enucleation or evisceration should not be performed be-
cause of an initial vision of NLP alone, since Agrawal et
al. [32] found that one third of traumatized eyes with a
preoperative visual acuity of NLP had ambulatory vision
or better after surgery. Other reports also showed im-
provement of NLP vision after surgical repair due to ad-
vances in vitreoretinal surgery [33–35]. Moshfeghi et al.
[24] also reported that intraocular tumors were the sec-
ond leading cause of enucleation in 24 to 28 % of cases,
while only three patients in the current series had tu-
mors (two retinoblastoma and one choroidal melanoma).
Intraocular tumors accounted for 4.4 % of anophthalmic
Table 3 Indications for Enucleation and Evisceration surgery according to age
Age (Years) Trauma Endophthalmitis Glaucoma Keratitis Behcet’s disease Tumors Total
1–9 1 1 1 2 0 2 7
10–19 8 1 0 1 0 0 10
20–29 6 1 2 0 0 0 9
30–39 6 0 2 1 2 0 11
40–49 2 1 3 1 0 1 8
50–59 0 1 1 3 0 0 5
60–69 1 3 1 0 1 0 6
70–79 2 4 0 4 0 0 10
80–89 1 1 0 0 0 0 2
Total 27 13 10 12 3 3 68
Table 4 Indications for Enucleation and Evisceration surgery according to sex
Surgery Trauma Endophthalmitis Glaucoma Keratitis Behcet’s disease Tumor Total
Evisceration
Men 10 5 4 7 1 0 27
Women 4 7 1 3 0 0 15
Enucleation
Men 6 1 3 0 2 3 15
Women 7 0 2 2 0 0 11
Total 27 13 10 12 3 3 68
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surgery in the current series since almost all cases of
ocular tumors were referred and managed in a nearby,
specialized cancer center in Jordan that was established
in 1997 [36].
The complication rates of enucleation and evisceration
have ranged from 6 to 100 %, with erosion being the
most commonly encountered complication [24, 29, 37].
In the current series, around 1/3 of patients reported
minor or major local side effects, with wound dehiscence
and implant exposure being the most common (Table 5).
Even though insertion of the largest implant possible,
whether during an enucleation or evisceration procedure,
may be associated with increased risk of implant exposure
or extrusion, it can prevent enophthalmos and superior
sulcus deformity;[3] therefore, recent advances in evis-
ceration techniques largely focused on various types
of posterior sclerotomies to allow for placement of
larger implants (up to or even larger than 20 mm) in
a large percentage of patients [30, 38].
The impact of suturing the muscles in relation to the
implant for the sake of prosthesis motility after enucle-
ation is still a controversy in the literature. Some sur-
geons are suturing the muscles directly to the implant or
to a mesh around the implant, [29, 39, 40] while others
Fig. 1 The sizes of the silicone implant spheres in millimeters and their frequency in the evisceration subgroup
Fig. 2 The sizes of the silicone implant spheres in millimeters and their frequency in the enucleation subgroup
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suture the muscles together in front of the implant (im-
brication) [41]. In the other hand, some surgeons prefer
the myoconjunctival technique in which they suture the
muscles to the conjunctiva in the fornix rather than to
the implant and they report motility that is better than
suturing the muscles in front the implant and equal mo-
tility (with less migration, and exposure) to direct sutur-
ing of the muscle to an integrated implant [42, 43]. In
another technique (as we did in this series) the muscles
were cut near their insertions to the globe and left with-
out suturing to the implant nor in front of the implant,
with meticulous suturing of the tissues anterior to the
implant to decrease the risk of implant extrusion or ex-
posure. No single eye in this series had contracted
socket, and this is not unexpected for us basically since
no single patient in this series had received radiation
which is the most important risk factor for contracted
socket.
In cases of endophthalmitis, evisceration is preferred
to enucleation because evisceration is thought to have
less risk of postoperative meningitis or encephalitis [44].
In the current series,12 of the 13 patients with endoph-
thalmitis (92 %) underwent evisceration with silicone
sphere orbital implant insertion at the time of primary
surgery in an attempt to save the patient a secondary
implant insertion, which recently has been reported to
be most successful [4, 23, 44, 45]. We also did not notice
an increased risk of infection or implant extrusion in
these cases. Postoperative orbital infection developed in
three cases in the current series, i.e., in one patient after
a massive globe injury during a motor vehicle accident
with eyelid swelling and orbital pain 3 months after enucle-
ation and in one patient each after keratitis and endoph-
thalmitis. All three cases were treated conservatively with
oral antibiotics without removal of the orbital implant.
In the current series, the enucleation group was sig-
nificantly younger than the evisceration group (25.24 ±
16.50 years compared to 47.12 ± 24.11 years, p = 0.001),
which may be due to trauma and tumors; 23 of the
trauma patients were younger than 50 years and only
four patients were older than 50 years (Table 3), and
due to enucleations for retinoblastoma being done at
younger ages. Furthermore, patients who developed
endophthalmitis and keratitis usually had previous in-
traocular surgery and are of older age that primarily
underwent evisceration. In addition, since about two-
thirds of our trauma cases where men, we had a male
preponderance with a ratio of about 2:1, similar to
other reports [31, 46, 47].
Conclusion
Our results were similar to other reports from developed
and developing countries. The major causes for anophthal-
mic surgery remain trauma, a blind painful eye, and
endophthalmitis. Patients who require enucleation (mainly
as the result of trauma and tumors) were younger and
had larger implants than the patients who underwent
evisceration.
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